Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...

Fact checked by Jennifer Klump Key Takeaways The FDA approved the obesity drug Wegovy as a treatment for people with MASH ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO- ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...